Geneos Wealth Management Inc. Grows Stake in Vericel Co. (NASDAQ:VCEL)

Geneos Wealth Management Inc. grew its holdings in shares of Vericel Co. (NASDAQ:VCEL) by 826.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,511 shares of the biotechnology company’s stock after buying an additional 2,240 shares during the period. Geneos Wealth Management Inc.’s holdings in Vericel were worth $138,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Vericel by 22.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock worth $77,000 after buying an additional 322 shares during the period. Farther Finance Advisors LLC lifted its holdings in shares of Vericel by 48.1% during the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 405 shares during the last quarter. PFG Investments LLC boosted its position in shares of Vericel by 8.0% in the 3rd quarter. PFG Investments LLC now owns 7,400 shares of the biotechnology company’s stock worth $313,000 after purchasing an additional 550 shares in the last quarter. International Assets Investment Management LLC grew its stake in shares of Vericel by 4,126.7% in the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after buying an additional 619 shares during the last quarter. Finally, Advisors Asset Management Inc. grew its stake in shares of Vericel by 4.0% in the 3rd quarter. Advisors Asset Management Inc. now owns 16,890 shares of the biotechnology company’s stock worth $714,000 after buying an additional 644 shares during the last quarter.

Vericel Stock Up 0.5 %

Shares of Vericel stock opened at $59.25 on Friday. Vericel Co. has a twelve month low of $39.12 and a twelve month high of $61.99. The company has a market cap of $2.92 billion, a price-to-earnings ratio of 987.66 and a beta of 1.72. The company’s 50 day moving average is $57.66 and its 200 day moving average is $50.75.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03. The firm had revenue of $57.91 million for the quarter, compared to the consensus estimate of $55.32 million. Vericel had a return on equity of 1.48% and a net margin of 1.56%. Sell-side analysts expect that Vericel Co. will post 0.12 EPS for the current fiscal year.

Insider Activity

In other news, insider Jonathan Mark Hopper sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $58.72, for a total value of $587,200.00. Following the transaction, the insider now owns 58,371 shares of the company’s stock, valued at $3,427,545.12. This trade represents a 14.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert L. Md Zerbe sold 2,500 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $60.00, for a total value of $150,000.00. Following the transaction, the director now owns 26,595 shares of the company’s stock, valued at approximately $1,595,700. This trade represents a 8.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 19,008 shares of company stock valued at $1,132,129 in the last quarter. 5.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

VCEL has been the subject of several analyst reports. Stephens restated an “overweight” rating and set a $65.00 price target on shares of Vericel in a report on Wednesday, January 15th. Truist Financial raised their price objective on shares of Vericel from $61.00 to $67.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Vericel in a research note on Wednesday, January 15th. Canaccord Genuity Group reissued a “buy” rating and set a $60.00 price target on shares of Vericel in a research report on Tuesday, November 19th. Finally, BTIG Research upped their price objective on Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $62.14.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.